SciSparc Ltd. Ordinary Shares (SPRC)
FairStock Score: 43/100 — MIXED
Key Financials
| Current Price | $1.09 |
| Market Cap | $4M |
| P/E Ratio | 0.01 |
| ROE | -178.39% |
| Dividend Yield | —% |
| Sector | Healthcare |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
On 2026-10-13, SciSparc closed at $3.94, giving a market capitalization of just $3.7 million. The FairStock calculations show a P/B of 0.34, a P/E of 0.04, a Graham Number of $159.99, and a 97.54% margin of safety. Those figures look extraordinary, but Graham taught me to ask what earning power stands behind them. This is a clinical-stage cannabinoid drug developer with three employees. FairStock’s ROE is -178.39%, ROCE is -60.68%, the Piotroski F-Score is 2/9, and the Altman Z-Score is -14.60. That is not a durable business; it is a speculative biotech balance sheet. The debt/equity ratio of 0.07 is low, but leverage is not the problem—profitability and survival are. There is no Lynch category because only zero years of filed annual results were available, and revenue and profit growth are not provided. I cannot underwrite a competitive moat or a reliable growth trajectory from that. The 52-week range of $2.98 to $40.41 and a beta of 2.44 confirm extreme volatility. The apparent cheapness on P/E and Graham Number likely reflects accounting artifacts rather than a stable stream of owner earnings. In Buffett-Graham terms, I want a margin of safety in the business, not just a formula. Without visible durable profits or a multi-year record, the Graham Number is not a safety net. This looks like a lottery ticket, not a value investment.
In plain English: SciSparc is a very small drug company focused on cannabis-related medicines and hemp seed oil products. It has only three employees and very little debt, but it is losing money by the return measures and has no multi-year record, so the business looks weak and speculative. The stock price may look cheap against some accounting numbers, but those numbers are unusual and do not prove a stable, profitable business.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash
Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer